Determination of grade and receptor status from the primary breast lesion by magnetic resonance spectroscopy

Technology in Cancer Research and Treatment

Volumn 3, Issue 6, 2004, Pages 551-556

  Lean, Cynthia ^a   Doran, Sinead ^a   Somorjai, Ray L ^b   Malycha, Peter ^c   Clarke, David ^d   Himmelreich, Uwe ^a   Bourne, Roger ^a   Dolenko, Brion ^b   Nikulin, Alexander E ^b   Mountford, Carolyn ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b NATIONAL RESEARCH COUNCIL CANADA   (Canada)

^c UNIVERSITY OF ADELAIDE   (Australia)

^d Breast Center   (Australia)

Author keywords

Breast neoplasms; Fine needle aspiration spectroscopy (FNAS); Magnetic resonance; Receptor status; Statistical analysis; Tumor grade

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ARTICLE; ASPIRATION BIOPSY; BREAST CANCER; BREAST LESION; BREAST TUMOR; CANCER GRADING; HUMAN; HUMAN TISSUE; LYMPH NODE; MAJOR CLINICAL STUDY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOLOGY; PROGNOSIS; RELIABILITY; SENSITIVITY AND SPECIFICITY; STATISTICAL ANALYSIS; TUMOR DIAGNOSIS;

EID: 19944420807     PISSN: 15330346     EISSN: None     Source Type: Journal    
DOI: 10.1177/153303460400300604     Document Type: Article

References (27)

1. Mountford, C., Doran, S., Lean, C., and Russell, P. Proton MRS can Determine the Pathology of Human Cancers With a High Level of Accuracy. Chem. Rev. 104, 3677-3704 (2004).
2. Mountford, C. E., Doran, S., Lean, C. L., and Russell P. Cancer Pathology in the Year 2000. Biophys. Chem. 68, 127-135 (1997).
3. Lean, C. L., Delbridge, L., Russell, P. et al. Diagnosis of Follicular Thyroid Lesions by Proton Magnetic Resonance on Fine Needle Biopsy. J. Clin. Endocrinol. Metab. 80, 1306-1311 (1995).
4. Russell, P., Lean, C. L., Delbridge, L., May, G. L., Dowd, S., and Mountford, C. E. Proton Magnetic Resonance and Human Thyroid Neoplasia. I: Discrimination Between Benign and Malignant Neoplasms. Am. J. Med. 96, 383-388 (1994).
5. Barry. P. A., Wadstrom, C., Falk, G. D. et al. In The Oesophagrogastric Junction. Ed. Giuli, R. (1998).
6. Somorjai, R., Dolenko, B., Nikulin, A. et al. Distinguishing Normal Allografts from Biopsy-Proven Rejections: Application of a Three-stage Classification Strategy to Urine MR and IR Spectra. Vib. Spectros. 28, 97-102 (2002).
7. Lean, C. L., Somorjai, R. L., Smith, I. C. P., Russell, P., and Mountford, C. E. In Annual Reports NMR Spectroscopy, Vol. 48. Ed. Webb, G. Academic Press (2002).
8. 't Hart, B., Vogels, J., Spijksma, G., Brok, H., Polman, C., and van der Greef, J. 1H-NMR Spectroscopy Combined with Pattern Recognition Analysis Reveals Characteristic Chemical Patterns in Urines of MS Patients and Non-human Primates with MS-like Disease. J. Neurol. Sci. 212, 21-30 (2003).
9. Rush, D., Somorjai, R., Deslauriers, R., Shaw, A., Jeffery, J., and Nickerson, P. Subclinical Rejection - A Potential Surrogate Marker for Chronic Rejection - May be Diagnosed by Protocol Biopsy or Urine Spectroscopy. Ann. Transplant. 5, 44-49 (2000).
10. Mountford, C. E., Somorjai, R. L., Malycha, P. et al. Diagnosis and Prognosis of Breast Cancer by Magnetic Resonance Spectroscopy of Fine-needle Aspirates Analyzed using a Statistical Classification Strategy. Br. J. Surg. 88, 1234-1240 (2001).
11. Kerlikowske, K., Grady, D., Barclay, J., Sickles, E. A., and Ernster, V. Likelihood Ratios for Modern Screening Mammography. Risk of Breast Cancer Based on Age and Mammographic Interpretation. [Comment]. Jama. 276, 39-43 (1996).
12. Somorjai, R., Alexander, M., Baumgartner, R. et al. In Artificial Intelligence Methods and Tools for Systems Biology. Ed., Azuaje F, D. W. e. Kluwer Academic Publishers, Boston (in press) (2004).
13. Reo, N. V. NMR-Based Metabonomics. Drug & Chemical Toxicology 25, 375-382 (2002).
14. Hagberg, G. From Magnetic Resonance Spectroscopy to Classification of Tumors. A Review of Pattern Recognition Methods. NMR Biomed. 11, 148-156 (1998).
15. El-Deredy, W. A. Pattern Recognition Approaches in Biomedical and Clinical Magnetic Resonance Spectroscopy. NMR Biomed. 10, 99-124 (1997).
16. Australian Cancer Network Working Party. The Pathology Reporting of Breast Cancer, A Guide for Pathologists, Surgeons Radiologists and Oncologists. 2nd edition, October 2001.
17. Nikulin, A., Dolenko, B., Bezabeh, T., and Somorjai, R. Near-optimal Region Selection for Feature Space Reduction: Novel Preprocessing Methods for Classifying MR Spectra. NMR Biomed. 11, 209-217 (1998).
18. Mountford, C. E. and Mackinnon, W. B. Proton Magnetic Resonance Spectroscopy of Lymphocytes: an Historical Perspective. Immunomethods 4, 98-112 (1994).
19. Wright, L. C., May, G. L., Gregory, P. et al. Inhibition of Metastatic Potential by Fucosidase: An NMR Study Identifies a Cell Surface Metastasis Marker. J. Cell Biochem. 37, 49-59 (1988).
20. Lean, C. L., Mackinnon, W. B., Delikatny, E. J., Whitehead, R. H., and Mountford, C. E. Cell-surface Fucosylation and Magnetic Resonance Spectroscopy Characterization of Human Malignant Colorectal Cells. Biochemistry 31, 11095-11105 (1992).
21. Mackinnon, W. B., Huschtscha, L., Dent, K., Hancock, R., Paraskeva, C., and Mountford, C. E. Correlation of Cellular Differentiation in Human Colorectal Carcinoma and Adenoma Cell Lines with Metabolite Profiles Determined by 1H Magnetic Resonance Spectroscopy. Int. J. Cancer 59, 248-261 (1994).
22. Weidner, N. Prognostic Factors in Breast Carcinoma. Curr. Opin. Obstet. Gynecol. 7, 4-9 (1995).
23. Fisher, B., Ravdin, R. G., Ausman, R. K., Slack, N. H., Moore, G. E., and Noer, R. J. Surgical Adjuvant Chemotherapy in Cancer of the Breast: Results of a Decade of Cooperative Investigation. Ann. Surg. 168, 337-356 (1968).
24. Silverstein, M. J., Gierson, E. D., Waisman, J. R., Senofsky, G. M., Colburn, W. J., and Gamagami, P. Axillary Lymph Node Dissection for T1a Breast Carcinoma. Is it Indicated? Cancer 73, 664-667 (1994).
25. Chen, Y. Y. and Schnitt, S. J. Prognostic Factors for Patients with Breast Cancers 1cm and Smaller. Breast Cancer Res. Treat. 51, 209-225 (1998).
26. Jensen, E. V. and Jordon, V. C. The Estrogen Receptor: A Model for Molecular Medicine. Clin. Cancer Res. 9, 1980-1989 (2003).
27. Bardou, V. J., Arpino, G., Elledge, R. M., Osborne, C. K., and Clark, G. M. Progesterone Receptor Status Significantly Improves Outcome Prediction Over Estrogen Receptor Status Alone for Adjuvant Endocrine Therapy in Two Large Breast Cancer Databases. J. Clin. Oncol. 21, 1973-1979 (2003).